Osteonecrosis of the jaw

NewAmsterdam Pharma Appoints William H. Lewis, J.D., M.B.A. as Chair of its Board of Directors

Retrieved on: 
Monday, January 8, 2024
Dyslipidemia, Entrepreneurship, Science, Case Western Reserve University, NAMS, Government, Apolipoprotein, Trustee, Growth, Oberlin College, Patient, Cardiovascular disease, Osteonecrosis of the jaw, Pharmaceutical industry

Mr. Lewis has served as Chief Executive Officer of Insmed Incorporated, a global commercial-stage biopharmaceutical company, since 2012, and as Chair of Insmed’s Board of Directors since 2018.

Key Points: 
  • Mr. Lewis has served as Chief Executive Officer of Insmed Incorporated, a global commercial-stage biopharmaceutical company, since 2012, and as Chair of Insmed’s Board of Directors since 2018.
  • Mr. Lewis succeeds Sander Slootweg, Managing Partner at Forbion, who has served as Chairman of NewAmsterdam’s Board of Directors since inception.
  • I would also like to thank Sander for his support and contribution as our Chairman over the last several years.
  • I am excited to join NewAmsterdam’s Board of Directors and look forward to partnering closely with management to complete the ongoing Phase 3 program and bring obicetrapib forward.”

Chasing Breakthrough Innovation in a Time of Uncertainty With Insights from McKinsey & Company

Retrieved on: 
Tuesday, September 19, 2023
Chief technology officer, PTC Therapeutics, Senior, Doctor of Philosophy, Advocacy, Outcomes research, Horizon Therapeutics, Health care, PTC, Policy, Senior advisor, Ernst & Young, Osteonecrosis of the jaw, Bristol Myers Squibb, Insming, Cross-cultural communication, Director of Communications (Office of the Prime Minister), Indivior, Digital, Therapy, Pharmaceutical industry, Management

TRENTON, N.J., Sept. 19, 2023 /PRNewswire/ -- BioNJ has released the agenda and speaker roster for its Eleventh Annual C-Suite Summit, taking place Friday, October 6, 2023, at the Bridgewater Marriott. The C-Suite Summit brings together life sciences executives representing a wide breadth of companies from early to late stage, public and private and revenue and pre-revenue to discuss the topics impacting C-Suite decision-making in bringing new innovative treatments to market.

Key Points: 
  • Friday, October 6, 2023 • 7:30 a.m.-4:00 p.m. Bridgewater Marriott, 700 Commons Way, Bridgewater
    TRENTON, N.J., Sept. 19, 2023 /PRNewswire/ -- BioNJ has released the agenda and speaker roster for its Eleventh Annual C-Suite Summit, taking place Friday, October 6, 2023, at the Bridgewater Marriott.
  • The C-Suite Summit brings together life sciences executives representing a wide breadth of companies from early to late stage, public and private and revenue and pre-revenue to discuss the topics impacting C-Suite decision-making in bringing new innovative treatments to market.
  • "As the policy environment churns and investment in biopharma fluctuates, questions are being raised about the future of innovation for our industry," said BioNJ President and CEO, Debbie Hart.
  • "The C-Suite Summit allows stakeholders to come together for an open conversation on where the greatest opportunities lie and how to best prepare for and shape the next paradigm in life sciences and medical discovery."

Curio Digital Therapeutics Wins Most Innovative Company Award at BioNJ’s Biopartnering Conference

Retrieved on: 
Thursday, June 29, 2023
Research, Mental Health, Women, Baby, Maternity, Health Technology, Biotechnology, Alternative Medicine, Consumer, Health, Science, Therapy, Education, Premenstrual dysphoric disorder, Osteonecrosis of the jaw, Woman, IP, Paramount, Entrepreneurship, Patient, Ecosystem, Digital, Conference, Disease, Pharmaceutical industry, Nursing, Curio

Curio Digital Therapeutics, a digital therapeutics company focused on supporting women across the cycle of life, announced today that it has won the Most Innovative Company Award at BioNJ’s 12th Annual BioPartnering Conference.

Key Points: 
  • Curio Digital Therapeutics, a digital therapeutics company focused on supporting women across the cycle of life, announced today that it has won the Most Innovative Company Award at BioNJ’s 12th Annual BioPartnering Conference.
  • The BioPartnering Conference, held on May 9-11, 2022, brought together life sciences professionals from around the world to network, collaborate and showcase their innovative solutions.
  • Curio was selected as the winner of the Most Innovative Company Award by a panel of judges based on market opportunity, unmet need, overall innovation, differentiation and IP.
  • “We congratulate Curio on winning the Most Innovative Company Award and commend them for their dedication to improving the lives of women through their cutting-edge digital therapeutics solutions.”
    Curio Digital Therapeutics is a digital therapeutics company focused on supporting women across the cycle of life.

Levolta Pharmaceuticals Partners with Tabuk Pharmaceuticals for Commercialization of Investigational Osteoarthritis Therapy in Middle East and Africa

Retrieved on: 
Thursday, June 1, 2023
Ketan, Osteoarthritis, Business development, Partnership, Physical disability, Central nervous system, Arthritis, Disability, Osteonecrosis of the jaw, MEA, Multimedia, Musculoskeletal disorder, Phase II, OA, MRI, Patient, Council, Rheumatology, Joint, Human musculoskeletal system, Disease, Pharmaceutical industry, Kingdom

BETHLEHEM, Pa., June 1, 2023 /PRNewswire/ -- Levolta Pharmaceuticals , Inc. has entered into an exclusive licensing and distribution agreement for VOLT01 with Tabuk Pharmaceutical Manufacturing Company of Riyadh, Saudi Arabia, for the commercialization of an investigational osteoarthritis (OA) therapy in the Middle East and Africa (MEA) region, excluding South Africa.

Key Points: 
  • BETHLEHEM, Pa., June 1, 2023 /PRNewswire/ -- Levolta Pharmaceuticals , Inc. has entered into an exclusive licensing and distribution agreement for VOLT01 with Tabuk Pharmaceutical Manufacturing Company of Riyadh, Saudi Arabia, for the commercialization of an investigational osteoarthritis (OA) therapy in the Middle East and Africa (MEA) region, excluding South Africa.
  • Tabuk is the market leader in MEA and will be a valuable partner in fulfilling that mission."
  • Tabuk Pharmaceuticals, a fully owned subsidiary of Astra Industrial Group, will hold the marketing authorization and be responsible for registering, importing, and commercializing VOLT01 in the MEA region.
  • "At Tabuk Pharmaceuticals, we believe in our vital role to provide patients across the Middle East and Africa with unique healthcare solutions that support their wellbeing," said Mohammed Al Hagbani, CEO of Tabuk Pharmaceuticals and President of Astra Industrial Group.

BioNJ Releases New Report: Health Equity in Clinical Trials MBA Business Case Competition: Identifying Innovative Approaches to Strengthening Diversity Within Clinical Trials

Retrieved on: 
Tuesday, April 18, 2023
Rutgers Business School – Newark and New Brunswick, PTC Therapeutics, Senior, Advocacy, Rice University, Policy, Rare disease, Initiative, Health equity, Baylor University, The Palace, MBA, Bristol Myers Squibb, Thermo Fisher Scientific, Mentorship, Report, Rutgers University, Student, Committee, Johns Hopkins University, Psychology, Chairperson, Baylor College of Medicine, Patient, Ecosystem, Therapy, Conference, Safety, Pharmaceutical industry, Osteonecrosis of the jaw, Medidata Solutions

TRENTON, N.J., April 18, 2023 /PRNewswire/ --  During today's 13th Annual BioPartnering Conference, taking place live at The Palace in Somerset Park, BioNJ, New Jersey's life sciences trade association, released its "Health Equity in Clinical Trials MBA Business Case Competition: Identifying Innovative Approaches to Strengthening Diversity Within Clinical Trials." 

Key Points: 
  • TRENTON, N.J., April 18, 2023 /PRNewswire/ --  During today's 13th Annual BioPartnering Conference, taking place live at The Palace in Somerset Park, BioNJ, New Jersey's life sciences trade association, released its " Health Equity in Clinical Trials MBA Business Case Competition: Identifying Innovative Approaches to Strengthening Diversity Within Clinical Trials ."
  • The competition was designed to promote the next generation of diverse clinical trial innovators and identify innovative approaches and successful models that can be used nationally to strengthen diversity in clinical trials and expand health equity.
  • In 2022, the organization launched its Health Equity in Clinical Trials Initiative to identify long-term interventions, support companies to improve equity in their clinical trials, consider best practices and shape and impact policy.
  • " said Amadou Diarra, Ph.D., Senior Vice President, Global Policy, Advocacy & Government Affairs, Bristol Myers Squibb; Board Chair, BioNJ; and inaugural Chair of the BioNJ Health Equity in Clinical Trials Initiative.

Hillstream BioPharma to Participate in Two Major Industry Conferences in April 2023

Retrieved on: 
Tuesday, March 28, 2023
Learning, Biotechnology, Ferroptosis, Trial of the century, Patient, Growth, Conference, Pharmaceutical industry, Osteonecrosis of the jaw, Hillstream loach

BRIDGEWATER, N.J., March 28, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers using ferroptosis, and immuno-oncology targeted novel biologics, today announced that its CEO Randy Milby will be participating – in person – at two major industry conferences in April 2023.

Key Points: 
  • BRIDGEWATER, N.J., March 28, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers using ferroptosis, and immuno-oncology targeted novel biologics, today announced that its CEO Randy Milby will be participating – in person – at two major industry conferences in April 2023.
  • The Company will present at the 2023 BioNJ BioPartnering Conference being held April 17-18, 2023 in Somerset, New Jersey.
  • Management will also attend the CPHI North America Conference being held April 25-27, 2023 in Philadelphia, Pennsylvania.
  • “Both the CPHI North America and BioNJ BioPartnering conferences are great opportunities to connect with investors and companies from throughout the pharma sector.

BioNJ Announces Lineup for BioPartnering Conference

Retrieved on: 
Tuesday, March 7, 2023
Transfer, Boston, Fireside chats, Ecosystem, Pulmonary hypertension, The Palace, European Institute of Innovation and Technology, Capital, Patient, Boston Millennia Partners, Student, J. P. Morgan, Janssen Pharmaceuticals, Columbia University, Innovation, Johnson & Johnson, Osteonecrosis of the jaw, Intellectual property, Human back, Conference, CFO, Organization, Health equity, Associate, Health, Pharmaceutical industry, Science, Retina

TRENTON, N.J., March 7, 2023 /PRNewswire/ -- BioNJ is pleased to host its 13th Annual BioPartnering Conference on Tuesday, April 18, 2023, at The Palace at Somerset Park, Somerset, NJ.

Key Points: 
  • TRENTON, N.J., March 7, 2023 /PRNewswire/ -- BioNJ is pleased to host its 13th Annual BioPartnering Conference on Tuesday, April 18, 2023, at The Palace at Somerset Park, Somerset, NJ.
  • "We're thrilled to partner once again with J.P. Morgan and Johnson & Johnson Innovation on BioNJ's BioPartnering Conference, and are ecstatic to have Morgan Lewis join this elite group of Conference Partners for 2023.
  • These organizations are dedicated to strengthening the ecosystem and supporting the life sciences industry in bringing new therapies and medicines to Patients," said Debbie Hart, President and CEO, BioNJ.
  • The action-packed schedule is designed to foster productive partnerships, create meaningful opportunities, grow the ecosystem and bolster medical innovation.

Aziyo Biologics Comments on June 2nd Voluntary Recall of One Lot of its FiberCel Fiber Viable Bone Matrix

Retrieved on: 
Monday, June 7, 2021
Musculoskeletal system, Anatomy, Medical specialties, Bone, Bones, Connective tissue, Skeletal system, Transplantation medicine, Bone grafting, Osteonecrosis of the jaw

At present, the Company has no reason to believe any other units of FiberCel are affected by this situation.

Key Points: 
  • At present, the Company has no reason to believe any other units of FiberCel are affected by this situation.
  • FiberCel is a fiber-based bone repair product made from human tissue and engineered to maintain characteristics of natural tissue.
  • FiberCel provides handling properties that are critical for use as a bone void filler in various orthopedic and spinal procedures.
  • FiberCel contains cancellous bone particles with preserved living cells and demineralized cortical bone fibers to facilitate bone repair and healing.

Promising New Treatment Plan for Jaw Osteonecrosis

Retrieved on: 
Tuesday, December 10, 2019
Dentistry, Osteonecrosis, Health, Medical specialties, Medication related osteonecrosis of the jaw, Osteonecrosis of the jaw, Bisphosphonate, Dental implant, Avascular necrosis, C-terminal telopeptide

One such complication is bone tissue death, known as osteonecrosis, which can result when patients take drugs, such as bisphosphonates, for bone diseases.

Key Points: 
  • One such complication is bone tissue death, known as osteonecrosis, which can result when patients take drugs, such as bisphosphonates, for bone diseases.
  • However, a recent case study in the Journal of Oral Implantology describes the successful treatment of a patient with osteonecrosis by using a new regimen.
  • The clinicians detailed numerous improvements that were seen throughout the treatment period as well as 6 months after the treatment.
  • Full text of the article "Treatment of Medication-Related Osteonecrosis of the Jaw Around the Dental Implant With a Once-Weekly Teriparatide: A Case Report and Literature Review," Journal of Oral Implantology, is available at https://doi.org/10.1563/aaid-joi-D-19-00040 .